Actively Recruiting
Evaluating the Addition of a Digital Treatment Tool to Obesity Medication in Adolescents with Obesity
Led by Karolinska Institutet · Updated on 2026-09-10
40
Participants Needed
3
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding a digital-physical treatment tool called Evira to obesity medications can improve treatment outcomes for adolescents aged 12 to 17 with obesity. This randomized controlled study compares the combined use of Evira and medications liraglutide or semaglutide against medication treatment alone. The trial aims to address challenges in sustaining weight loss after stopping medication and improve treatment adherence and effectiveness. Participants are randomly assigned in a 21 ratio to either receive obesity medication plus the Evira digi-physical tool or medication alone with standard clinic support. Evira includes a digitless home measuring scale linked to a mobile app that shows weight trends using BMI standard deviation scores and allows communication between families and healthcare providers. The study follows participants for six months, monitoring physical health and treatment adherence. During the study, participants will undergo physical exams, provide background information, and complete electronic questionnaires. Researchers will measure changes in BMI SDS over six months as the primary outcome. Secondary measures include treatment adherence, side effects, perceptions of the digital tool by patients and professionals, and quality of life. Data from the home measurements and clinic communications will help assess the digital tools impact alongside medication therapy.
CONDITIONS
Brief Title
The Evira Study: Additional Support During Obesity Treatment
Research Team
P
Pernilla Danielsson Liljeqvist, Associate Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here